Drugs Made In America Acquisition Corp Rights
DMAAR
32 hedge funds and large institutions have $7.1M invested in Drugs Made In America Acquisition Corp Rights in 2025 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
220% more capital invested
Capital invested by funds: $2.22M → $7.1M (+$4.88M)
33% more funds holding
Funds holding: 24 → 32 (+8)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$158K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$107K |
| 3 |
AGM
Alpine Global Management
New York
|
+$67.4K |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$60.4K |
| 5 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$59.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$176K |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$132K |
| 3 |
CA
Crossingbridge Advisors
Pleasantville,
New York
|
-$106K |
| 4 |
HCM
Heights Capital Management
San Francisco,
California
|
-$64K |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$60.1K |
DMAAR Hedge Fund Activity: Q3 2025 in Review
32 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q3 2025, worth a combined $7.1M — up 220% from $2.22M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DMAAR positions and 3 closed out — a net gain of 8 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was Linden Advisors, opening a new position worth an estimated $158K. The largest seller was Toronto Dominion Bank, cutting an estimated $176K.
- 32 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q3 2025, up from 24 in Q2 2025.
- Funds reported $7.1M of Drugs Made In America Acquisition Corp Rights stock for Q3 2025, up 220% quarter-over-quarter.
- 11 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q3 2025 and 3 closed out, a net change of +8 holders.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q3 2025 was Linden Advisors, an estimated $158K added.
- The largest Drugs Made In America Acquisition Corp Rights seller in Q3 2025 was Toronto Dominion Bank, an estimated $176K sold.
Based on aggregated 13F filings for Q3 2025.